CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Not Applicable

Recruiting

• Conditions: Lymphoma, B-Cell
• Interventions: Drug: chimeric antigen receptor gene modified T cells

• Registration Number: NCT06850285
• Lead Sponsor: Shanxi Bethune Hospital

Brief Summary

The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。

Detailed Description

The goal of this clinical trial is to explore the effect of CD30 CAR-T on CD30 positive relapsed/refractory lymphoma. The main questions it aims to answer are:

To evaluate the safety of autologous CD30 CAR-T therapy in CD30-positive relapsed/refractory lymphoma; To evaluate the efficacy of autologous CD30 CAR-T therapy for CD30-positive relapsed/refractory lymphoma; To evaluate the metabolism of CD30 CAR-T cells in vivo; Preliminary evaluation of the correlation between CAR T cell dose and clinical efficacy.

Study Timeline

• Status Verified: 2024-03
• Study First Submitted: 2025-02-23
• Study First Submitted QC: 2025-02-23
• Last Update Submitted: 2025-02-23
• Study First Posted: 2025-02-27
• Last Update Posted: 2025-02-27
• Study Start: 2025-09-05
• Primary Completion: 2028-06-01
• Study Completion: 2028-06-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Age≥15 years and ≤80years，female and male；
• CD30+ lymphocyte malignancies;
• CD30 expression >10% by immunohistochemistry；
• At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;
• Not suitable for autologous hematopoietic stem cell transplantation or recurrence after autologous hematopoietic stem cell transplantation;
• Not suitable for BV treatment or relapse after BV treatment, and the expression of CD30 was confirmed by histology;
• The estimated survival time ≥3 months;
• ECOG performance status 0-2，KPS>60%;
• Sufficient organ function：ALT，AST≤2.5×ULN，patients with liver invasion can be relaxed to ≤ 5 x ULN；serum total bilirubin<34 μmol/L；creatinine clearance rate>30 mL/min；EF≥40%；No pericardial effusion and obvious arrhythmia；SpO2≥92%；
• ALC ≥0.5×109/L，PLT>30×109/L，Hb>80 g/L and subjects had apheresis venous access and no contraindications for blood cell separation;
• MRI showed no central involvement of lymphoma;
• Patients with fertility must be willing to be able to use reliable contraceptive measures ;
• The subject or legal guardian can understand and voluntarily sign the written informed consent.

Exclusion Criteria

• Lymphoma-associated hemophagic cell syndrome;
• Pregnant or lactating women, and women who have a pregnancy plan within six months;
• Hepatitis B（HBsAg、HBsAb、HBeAg、HBeAb、HBcAb），Hepatitis C（Anti-HCV），Anti-HIV Ⅰ/Ⅱ and anti-TP positive（Hepatitis B DNA test is negative except）;
• Suffered from other malignant tumors, except for for skin basal cell carcinoma, skin squamous cell carcinoma and cervical carcinoma in situ undergoing the radical treatment;
• Received Anti-CD30 Ab therapy within 4 weeks before enrollment;
• Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments;
• Active uncontrolled bleeding or a known bleeding diathesis;
• Autologous hematopoietic stem cell transplantation was performed within 6 weeks;
• Uncontrollable active bacterial or fungal infection；
• Known allergy to the study drug and its components;
• Suffer from active autoimmune diseases that require systemic treatment ;
• Persons with mental or mental illness who cannot cooperate with treatment and efficacy evaluation;
• Participated in other clinical studies within 1 months prior to this study;
• History of allogeneic hematopoietic stem cell transplantation;
• patients with any condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Group1	chimeric antigen receptor gene modified T cells	Subjects received a single low-dose CD30 CAR-T therapy(1\*10\^6/kg CAR+T cells)
Group2	chimeric antigen receptor gene modified T cells	Subjects received a single low-dose CD30 CAR-T therapy(2\*10\^6/kg CAR+T cells)
Group3	chimeric antigen receptor gene modified T cells	Subjects received a single low-dose CD30 CAR-T therapy(5\*10\^6/kg CAR+T cells)

Primary Outcome Measures

Name	Time	Method
Overall response rate	6 months	Including complete remission (CR) and partial remission (PR)
To evaluate safety and dose limiting toxicities (DLT) of autologous CD30 CAR-T and establish the recommended Phase dose	28 days	Incidence of DLTs and occurrence of study related adverse events

Secondary Outcome Measures

Name	Time	Method
Disease-free survival	3years	DFS was calculated from the first CAR-T cell infusion to death, progression of the disease, relapse or gene recurrence, whichever came first, or last visit.
Overall Survival	3 years	OS was calculated from the first CAR-T cell infusion to death or last follow-up

Trial Locations

Locations (1)

Shanxi Bethune Hospital; 🇨🇳 Taiyuan, Shangxi, China